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The increased survival after acute myocardial infarction induced an increase in heart failure with left ventricular systolic
dysfunction. Early detection and treatment of asymptomatic left ventricular systolic dysfunction give the chance to improve
outcomes and to reduce costs due to the management of patients with overt heart failure.
1. Introduction
Despite substantial progresses in the diagnosis and treatment
of acute myocardial infarction (AMI), about 22% of men
and 46% of women will be disabled with heart failure (HF)
within six years [1]. About 40% of patients with an AMI
develop left ventricular systolic dysfunction (LVSD) with or
without signs of HF, which adversely influences quality of
life, hospitalization rates, and mortality [2]. Considering the
high survival rate after an AMI and the higher incidence
of LVSD, early detection of people at risk of developing
HF after an AMI should constitute a priority. Patients who
have had an AMI, but who do not show signs of HF, could
be burdened with an asymptomatic LVSD or stage B HF
(Figure 1), according to ACC/AHA Guidelines of 2009 [3].
This condition is often not diagnosed and, for this reason,
not treated, even if morbidity and mortality are similar to
those of symptomatic HF [3]. Besides this, these patients run
a higher risk because they are not aware of their pathology.
Our aim is to underline the importance of an early detection
of patients with asymptomatic LVSD in order to take all
the measures that are necessary to reduce morbidity and
mortality connected to this condition.
2. Epidemiology
In occidental countries, coronary heart disease (CHD) is
the most important cause of LVSD and HF [4]. Ischemic
cardiomyopathy is the underlying cause in about 61% of
patients with signs and symptoms of HF [5]. In the SAVE
trial, asymptomatic LVSD was present in 58% of patients
after an AMI [6]. Robust epidemiological data about the
prevalence of asymptomatic LVSD after an AMI are hard to
find. Surveys indicate that only about 60% of patients with an
AMI have their ventricular function assessed [7]. Hellermann
et al. conducted a review of the literature between 1978 and
2000, finding that the incidence of HF was reported only in
few studies and in none of these studies diagnostic criteria
for assessing HF were given [8]. If the Killip classification is
used, patients with asymptomatic LVSD should be classified
as Killip class 1 (no evidence of pulmonary congestion or
shock). Possibly the most relevant data on the incidence,
prevalence, and persistence of post-MI heart failure can be
derived from the TRACE study, a randomized, double-blind,
and placebo-controlled study in which patients who have had
an AMI were randomly assigned to receive oral trandolapril
or placebo [9]. About 40% of patients from the TRACE trial
developed LVSD and, among these, 74% developed clinical
features of HF. Besides this, only 30% of all patients had both
HF and LVSD, while 24% had features of HF in the absence
of LVSD. 64% of patients developed HF or LVSD within the
first few days after an AMI. TRACE results are corroborated
by other population studies in which the reported incidence
ofHF is 22%–48%,with amean of 37% [8]. GISSI-3 Echo sub-
study gives another important contribution to define LVSD
soon after an AMI [10]. Using end-diastolic volume (EDV)
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Figure 1: Stages of heart failure (Adapted from [3]).
as a marker of ventricular remodeling, the authors noted
that
(1) at 24–48 hours from symptoms onset and at hospital
discharge, EDV decreased in 26% of patients, was
stable in 23%, and increased slightly in 32%. Nineteen
percent of patients showed a>20% increase at hospital
discharge (severe early dilation);
(2) in the period between hospital discharge and six
months after AMI, EDV decreased in 31% of patients,
was stable in 25%, and slightly increased in 26%.
Sixteen percent of patients showed a >20% increase
at six months (severe late dilation);
(3) in-hospital left ventricular enlargement is not predic-
tive of subsequent dilation and dysfunction, while late
remodeling is associated with progressive deteriora-
tion of ventricular function [10]. The QRS complex
changes after AMI have been correlated with infarct
size and left ventricular function; by contrast, the
significance of T waves changes is not clear. GISSI-
3 study showed that normalization of negative T
waves during the followup was more correlated with
the resolution of wall motion abnormalities than
QRS changes; the absence of resolution or the late
appearance of new negative T waves predicts remod-
eling with progressive deterioration of left ventricular
function [11].
3. Prognosis
Patients with HF and LVSD have a higher risk of adverse
events (cardiac arrest, myocardial rupture, stroke, prolonged
hospitalization, ventricular arrhythmias, re-AMI, and sudden
death) than patients who have had an AMI but did not
develop LVSD or HF [12, 13]. In the SAVE trial, authors
enrolled patients with AMI and asymptomatic LVSD that
were followed up for an average of 42 months. About 16%
of patients, who survived after an AMI and with an ejection
fraction (EF) = 40%, developed clinical features of HF.
Besides this, 16% of patients in the placebo group had a
deterioration of EF of 9 or more units. Mortality rate in the
placebo group was 25% (12% within the first year) [14]. Also
VALIANT trial showed that LVSD after an AMI is correlated
to a higher incidence of sudden death. More than a half of
deaths classified as sudden death or cardiac arrest happened
among survivors of AMI with an EF = 30% [15].
4. Physiopathology
In LVSD following AMI, the AMI is the leading cause of
the deterioration of contractility and the decrease of EF
(Figure 2). The prototypic pathways that participate in main-
taining blood pressure and cardiac output include the
autonomic nervous system, renin-angiotensin-aldosterone
system, and cytokine cascades. In addition to the posi-
tive cardiac effects on stabilizing myocardial performance,
increasedmyocardial adrenergic signaling can lead to further
cardiac damage [15]. Nowadays it is a common opinion that
norepinephrine, angiotensin II, endothelin, aldosterone, and
tumor necrosis factor contribute to worsen LVSD and to the
passage from stage B to stage C of HF. The enlargement of
left ventricle associated to the modification of its shape that
also involves normal myocardial segments causes an increase
of left ventricular end-diastolic wall stress (afterload): this
results in the augmentation of the stroke work and in the
decrease of cardiac output. A high left ventricular end-
diastolic pressure in patients with asymptomatic LVSD is
related to a lower EF and is an independent predictor of
mortality and/or clinically overt HF [6]. So, the blockade of
neurohormonal activity may reverse ventricular remodeling,
preventing progression to symptomatic HF [16–18]. Other
risk factors, specific for the patient (such as older age,
diabetes, and hypertension) can partecipate to the process of
left ventricular remodeling after an AMI [19, 20].
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Figure 2: Physiopathology of left ventricular systolic dysfunction after myocardial infarction.
5. Diagnosis
The absence of clinical signs and symptoms of HF after
AMI may reflect the delay in the process of diagnosis and
therapeutic measures. For this reason, an early recognition
of this condition is important. The rationale is twofold.
First of all, randomized studies showed that an appropriate
therapy can improve significantly the prognosis. SOLVD
prevention trial showed that the angiotensin-converting-
enzyme inhibitor enalapril significantly reduced the inci-
dence of deaths, hospitalization rate, and HF, as compared
with the rates in the group given placebo (30% and 39%,
resp.), among patients with asymptomatic LVSD and this
treatment for 3-4 years led to an improvement of survival
in a 12-year followup [21, 22]. Secondly, the prognosis is
worse if the therapy is started on later (Figure 3). SOLVD
treatment trial, despite confirming the benefit of enalapril
treatment compared to placebo, showed that mortality rate
at two years was 20% versus 25% in the placebo group [23].
Hence, the importance of assessing LVEF after anAMI,which
is also a quality indicator in the management of AMI [20].
Nowadays the echocardiography is the method of choice
for the assessment of left ventricular function. The limit of
LVEF (=35% or =40%) for the identification of LVSD is still
a matter of debate, even if the inverse relationship between
mortality and the deterioration of LVEF is demonstrated
[9, 14, 22]. Even though it cannot be considered a surrogate
of echocardiography, the determination of brain natriuretic
peptide (BNP) can be useful for the diagnosis of HF and
to predict LVSD and left ventricular remodeling after AMI
[24, 25]. However the therapeutic benefit is strongly related
to an LVEF = 35–40%.
6. Therapy
Current therapeutic approach to the preservation of left
ventricular function inAMI consists, on one side, in reducing
infarct size through the administration of ASA and, on
the other side, in decelerating or preventing left ventricular
remodeling and the deterioration of LVEF through the
administration of angiotensin-converting-enzyme inhibitors
and 𝛽-blockers [26–29]. This therapeutic strategy is also
associated with a higher survival rate [9, 14, 18, 21, 30, 31].
6.1. ACE Inhibitors. Two important clinical trials, SAVE and
TRACE, demonstrated that long-term ACEi treatment, if
started early after AMI in patients with asymptomatic LVSD,
could prevent progression to overt symptoms and improve
survival. In the SAVE study survivors of AMI were followed
up for an average of 42 months: the reduction in the risk of
death from all causes in the group treated with captopril was
19%, the reduction in the risk of death due to cardiovascular
causes was 21%, and the reduction in the risk of developing
overt HF was 37% [14]. In the TRACE study, over 2–4 years,
there was a reduction of the overall mortality rate (22%), of
sudden death (24%), and of progression to overt HF (29%)
[9]. Several studies have evaluated the efficacy of ACEi in
patients in the acute phase of a myocardial infarction. The
efficacy of this strategy seems to be strictly related to reper-
fusion therapy. SMILE study demonstrated that the early
administration of zofenopril to patients with anterior AMI
who were not receiving thrombolytic therapy significantly
reduced the combined endpoint of death and severe HF at
six weeks from 10.6% to 7% [32]. Interestingly the benefits of
this short-term treatment were maintained over time, with
an improved survival at one year. A meta-analysis of 845
patients with anterior AMI could not demonstrate regression
of left ventricular dilation in patients receiving thrombolysis
by ACEi treatment, while very early treatment with ACEi has
a beneficial effect in patients in whom reperfusion therapy
failed [33].
6.2. Angiotensin-Receptor Blockers (ARBs). No clinical trials
using these agents in patients with LVSD have yet been
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Figure 3: Pharmacological and nonpharmacological therapies of stage B heart failure (Adapted from [3]).
reported. However, on the basis of studies such as CHARM-
Alternative and Val-HeFT and of pathophysiological and
clinical aspects, ARBs should be considered in patients
intolerant to ACEi. Combination therapy with an ACEi and
an ARB is not currently recommended in this category of
patients [34].
6.3. Beta Blockers (BB). BB are administrated to the majority
of patients after AMI, independently of the evaluation of
LVSD, because they are safe and effective in improving
survival rate and reducing the incidence of sudden death
and reinfarction.Their efficacy onmorbidity andmortality in
patients with asymptomatic LVSD is not clear. The CAPRI-
CORN randomized trial showed that, in patients treated a
long term after AMI complicated by LVSD, carvedilol in
combinationwith ACEi compared to placebo groups reduced
the frequency of all-cause (12% versus 15%, 𝑃 = 0.03) and
cardiovascular mortality and recurrent, nonfatal myocardial
infarction [18]. A retrospective analysis of data from the
SAVE study showed that the use of BB was significantly
associated with lower 1-year cardiovascular mortality (13%
versus 22% in patients without BB) and lower occurrence
of severe HF (17% versus 23% in patients without BB) [30].
REVERT study demonstrated that BB therapy can ameliorate
left ventricular remodeling in patients with asymptomatic
LVSD [35]. In the end, BB and ACEi are probably effective
also in elderly patients with asymptomatic LVSD, even if these
patients are less likely to receive this combined therapy. A
retrospective analysis of patients aged ≥ 65 years old showed
beneficial effects of BB in combination with ACEi among
elderly patients with asymptomatic LVSD if compared to
patients who received BB or ACEi or none [36].
6.4. Aldosterone Antagonists. Even though aldosterone
antagonists are effective in reducing morbidity and
mortality in patients with overt HF, they are not currently
recommended in patients with asymptomatic LVSD [34].
Ongoing trials are evaluating their benefit in decelerating the
process of left ventricular remodeling.
6.5. Digoxin. DIG study showed that digoxin did not reduce
the overall mortality but reduced hospitalization rate and
symptoms of HF [37].Thus, it is not recommended in asymp-
tomatic patients with LVSD, also because of its proarrhythmic
effects, especially in women [38].
6.6. Other Drugs. No studies evidenced the beneficial effects
of diuretics, nitrates, and calcium channel blockers in patients
with asymptomatic LVSD following AMI. BEAUTIFUL trial
showed no advantages in terms of cardiac outcomes in
the use of ivabradine in patients with chronic ischemic
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cardiomyopathy, asymptomatic LVSD (LVEF < 40%), and
history of myocardial infarction; on the other hand, it could
be administered to reduce the incidence of coronary artery
disease outcomes in a subgroup of patients who have heart
rates ≥ 70 bpm [39].
6.7. Nonpharmacological Therapy. Although drug therapy is
effective in the majority of patients in decreasing mortality
rate, the risk of death in patients with LVSD is still very
high. This category is burdened with a mortality rate at 4-
5 years of 20% [40]. MADIT-II enrolled 1232 patients (461
asymptomatic) with a prior myocardial infarction and LVEF
≤30%; these patients were randomly assigned to receive an
implantable defibrillator or conventional medical therapy.
Prophylactic implantation of a defibrillator improved sur-
vival with a reduction in 20-month mortality rate of 31%
[41]. Asymptomatic patients got the same beneficial effects
as symptomatic patients. Another trial, the DINAMIT, in
patients with a prior AMI, LVEF = 35%, and depressed heart
rate variability, showed that prophylactic ICD therapy does
not reduce overall mortality in high-risk patients who have
recently had a myocardial infarction. Although ICD therapy
was associated with a reduction in the rate of death due
to arrhythmia, that was offset by an increase in the rate of
death from nonarrhythmic causes [42]. Current European
Guidelines recommend the implantation of ICD in patients
with symptomatic or asymptomatic LVSD (LVEF 30–35%) 40
days after AMI and 3 months after an effective reperfusion
therapy [43]. The usefulness of resynchronization therapy
(CRT) in patients with asymptomatic LVSD is debatable.
REVERSE and MADIT-CRT studies suggest that it has no
efficacy in patients in NYHA functional class I-II. Thus, it is
not currently recommended in this group of people [44, 45].
Patients with LVSD following AMI are at high risk of
adverse events and, for this reason, therapy at discharge
should be optimized. Data from the National Registry of
Myocardial Infarction (NRMI) demonstrated that patients
who suffered from HF during stay in hospital underwent
less frequently the appropriate therapeuticmanagement [46].
All the preventive measures should be taken into account
in order to avoid anatomical and pathophysiological mod-
ifications that can lead to overt HF. “Overt HF should be
considered a defeat rather than the first indication to treat”
[47].
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